Journal article
Toll-like receptor 3 is necessary for dsRNA adjuvant effects.
- Salaun B Division of Clinical OncoImmunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (CHUV, Lausanne) and Epalinges, Switzerland. bruno.salaun@isrec.unil.ch
- Greutert M
- Romero P
- 2009-02-07
Published in:
- Vaccine. - 2009
Adjuvants, Immunologic
Adsorption
Aluminum Hydroxide
Animals
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Body Temperature
DNA
Ethylene Glycols
Extracellular Fluid
Humans
Hydrogen-Ion Concentration
Indicators and Reagents
Isoelectric Focusing
Mice
Sheep
Thermodynamics
Toll-Like Receptor 3
Vaccines
English
Toll-like receptors (TLR) recognize pathogen associated molecular patterns, and the binding of their specific ligands triggers a proinflammatory response that helps to fight invading microorganisms, and can be harnessed to increase vaccine efficiency. The present study demonstrates that double-stranded RNA is a promising vaccine adjuvant able to increase both proliferation and activation of antigen-specific CD8(+) T cells. Importantly, TLR3 is required for this adjuvant effect, as TLR3 deficient recipients failed to enhance proliferation of adoptively transferred TCR transgenic CD8(+) T cells in the presence of double-stranded RNA. Finally, this study also shows that, in contrast to previous reports in humans, TLR3 does not exert direct costimulatory activity on CD8(+) T cells in mice.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.vaccine.2009.01.044
- PMID 19195489
- Persistent URL
- https://sonar.ch/global/documents/78519
Export to…
Statistics
Document views: 51
File downloads: